Skip to search formSkip to main contentSkip to account menu

PNU-214565

Known as: C242Fab-SEA Immunotoxin 
A recombinant fusion protein of the bacterial superantigen Staphylococcal enterotoxin A (SEA) and the variable Fab fragment of the C242 monoclonal… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2000
2000
Phase I study of single, escalating doses of a superantigen-antibody fusion protein (PNU-214565) in patients with advanced colorectal or pancreatic carcinoma.
To develop a T-cell-based therapy for carcinomas, the superantigen staphylococcal enterotoxin A (SEA) was supplied with tumor… 
1998
1998
Superantigen-targeted therapy: phase I escalating repeat dose trial of the fusion protein PNU-214565 in patients with advanced gastrointestinal malignancies.
Antibody-directed, superantigen-induced cytotoxicity has been shown to have potent in vitro and in vivo antitumor effects in… 
Review
1998
Review
1998
Overview of clinical trials employing antibody-targeted superantigens.
Highly Cited
1997
Highly Cited
1997
Superantigen-based immunotherapy: a phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer.
PURPOSE To establish the maximum-tolerated dose (MTD) and define the toxicities of a single-dose infusion of PNU-214565, a… 
1997
1997
A phase I trial of escalating repeated doses of PNU-214565 in patients with advanced colorectal and other gastrointestinal adenocarcinomas
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)